Trial reportCritical care (London, England)2014
Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.
Trial report in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 90 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
Bioelectrical Impedance Vector Analysis (BIVA) in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients
Who cites it
90 citing papers in PubMed, 8 syntheses or guidelines pooled it, 237 citations in OpenAlex.
- Diagnostic performance of procalcitonin and presepsin in sepsis: a systematic review and meta-analysis.BMC emergency medicine · 2025Pooled it
- Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.The Cochrane database of systematic reviews · 2019Pooled it
- The delta neutrophil index (DNI) as a prognostic marker for mortality in adults with sepsis: a systematic review and meta-analysis.Scientific reports · 2018Pooled it
- Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis.PloS one · 2018Pooled it
- The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis.Critical care (London, England) · 2015Pooled it
- Pooled it
- Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis.PloS one · 2015Pooled it
- Bioelectrical Impedance in Monitoring Hyperhydration and Muscle Wasting in Critically Ill Corona Virus Disease (COVID-19) Patients: The Feasibility of Predicting Outcome.Physiological research · 2025Trial
- Valuable Role of Neutrophil CD64 and Highly Sensitive CRP Biomarkers for Diagnostic, Monitoring, and Prognostic Evaluations of Sepsis Patients in Neonatal ICUs.BioMed research international · 2020Trial
- The Analysis of Etiology and Risk Factors for 192 Cases of Neonatal Sepsis.BioMed research international · 2017Trial
- Systemic immune-inflammation (SII) index as a novel prognostic biomarker in critically ill patients with sepsis: analysis of the MIMIC-IV cohort and predictive modeling based on machine learning.BMC infectious diseases · 2026Article
- The Inflammation-Presepsin Score as a Predictor of Mortality in Elderly Sepsis Patients (≥75 Years): A Pilot Study.International journal of general medicine · 2026Article
- Role of cytokine levels in pathogen classification and prognosis of pediatric septic shock.Frontiers in immunology · 2026Article
- The value of plasma presepsin as a diagnostic and prognostic biomarker for febrile neutropenia in children.Annals of medicine · 2025Article
- Calprotectin, Azurocidin, and Interleukin-8: Neutrophil Signatures with Diagnostic and Prognostic Value in Sepsis.Biomedicines · 2025Article
- Review
- Evaluation of Presepsin for Early Diagnosis of Sepsis in the Emergency Department.Journal of clinical medicine · 2025Article
- Biomarkers Affecting Treatment Outcomes of Febrile Neutropenia in Hematological Patients with Lymphomas: Is Presepsin the New Promising Diagnostic and Prognostic Biomarker?Journal of clinical medicine · 2025Article
- Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups.Journal of clinical medicine · 2024Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study was to evaluate the diagnostic and prognostic value of presepsin in patients with severe sepsis and septic shock during the first week of ICU treatment.
methodsIn total, 116 patients with suspected severe sepsis or septic shock were included during the first 24 hours of ICU treatment. Blood samples for biomarker measurements of presepsin, procalcitonin (PCT), interleukin 6 (IL-6), C reactive protein (CRP) and white blood cells (WBC) were drawn at days 1, 3 and 8. All patients were followed up for six months. Biomarkers were tested for diagnosis of sepsis, severe sepsis, septic shock and for prognosis of 30-days and 6-months all-cause mortality at days 1, 3 and 8. Diagnostic and prognostic utilities were tested by determining diagnostic cutoff levels, goodness criteria, C-statistics and multivariable Cox regression models.
resultsPresepsin increased significantly from the lowest to most severe sepsis groups at days 1, 3 and 8 (test for linear trend P <0.03). Presepsin levels revealed valuable diagnostic capacity to diagnose severe sepsis and septic shock at days 1, 3 and 8 (range of diagnostic area under the curves (AUC) 0.72 to 0.84, P = 0.0001) compared to IL-6, PCT, CRP and WBC. Goodness criteria for diagnosis of sepsis severity were analyzed (≥sepsis, cutoff = 530 pg/ml; ≥severe sepsis, cutoff = 600 pg/ml; ≥septic shock, cutoff = 700 pg/ml; P <0.03). Presepsin levels revealed significant prognostic value for 30 days and 6 months all-cause mortality (presepsin: range of AUC 0.64 to 0.71, P <0.02). Patients with presepsin levels of the 4th quartile were 5 to 7 times more likely to die after six months than patients with lower levels. The prognostic value for all-cause mortality of presepsin was comparable to that of IL-6 and better than that of PCT, CRP or WBC.
conclusionsIn patients with suspected severe sepsis and septic shock, presepsin reveals valuable diagnostic capacity to differentiate sepsis severity compared to PCT, IL-6, CRP, WBC. Additionally, presepsin and IL-6 reveal prognostic value with respect to 30 days and 6 months all-cause mortality throughout the first week of ICU treatment.
trial registrationClinicalTrials.gov http://NCT01535534. Registered 14 February 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.